|
ATE364374T1
(de)
|
1997-08-11 |
2007-07-15 |
Pfizer Prod Inc |
Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
|
|
ATE369135T1
(de)
*
|
1998-04-24 |
2007-08-15 |
Scarista Ltd |
Behandlung von depression und zusammensetzungen dazu
|
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
|
BR9911049A
(pt)
*
|
1998-05-22 |
2001-02-06 |
Lilly Co Eli |
Terapia combinada para tratamento de depressão resistente
|
|
IL139591A0
(en)
*
|
1998-05-29 |
2002-02-10 |
Lilly Co Eli |
Combination therapy for treatment of bipolar disorders
|
|
AU1321900A
(en)
*
|
1998-10-23 |
2000-05-15 |
Sepracor, Inc. |
Compositions and methods employing r(-) fluoxetine and other active ingredients
|
|
US6174882B1
(en)
*
|
1998-11-23 |
2001-01-16 |
Sepracor Inc. |
2-hydroxymethylolanzapine compositions and methods
|
|
ES2306646T3
(es)
*
|
1999-02-09 |
2008-11-16 |
Pfizer Products Inc. |
Composiciones de farmacos basicos con biodisponibilidad incrementada.
|
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
AU3810100A
(en)
|
1999-03-12 |
2000-10-04 |
Basf Aktiengesellschaft |
Stable pharmaceutical application form for paroxetin anhydrate
|
|
CA2373855A1
(en)
*
|
1999-05-12 |
2000-11-23 |
Solvay Pharmaceuticals B.V. |
Method of treating psychotic disorders
|
|
WO2000071106A2
(en)
*
|
1999-05-19 |
2000-11-30 |
Astrazeneca Ab |
Method of treating weight gain
|
|
WO2000074784A1
(en)
*
|
1999-06-09 |
2000-12-14 |
Eli Lilly And Company |
Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
|
|
AR021155A1
(es)
*
|
1999-07-08 |
2002-06-12 |
Lundbeck & Co As H |
Tratamiento de desordenes neuroticos
|
|
EP1220658A1
(en)
*
|
1999-09-28 |
2002-07-10 |
H. Lundbeck A/S |
Melt granulated composition and modified release dosage form prepared from said composition
|
|
AU3789901A
(en)
|
1999-12-17 |
2001-06-25 |
Bristol-Myers Squibb Company |
Antipsychotic heterocycle compounds
|
|
GEP20053427B
(en)
|
1999-12-23 |
2005-01-25 |
Pfizer Prod Inc |
Pharmaceutical Compositions Providing Enhanced Drug Concentrations
|
|
US6572890B2
(en)
|
2000-01-13 |
2003-06-03 |
Osmotica Corp. |
Osmotic device containing venlafaxine and an anti-psychotic agent
|
|
EP1316203A2
(en)
*
|
2000-06-30 |
2003-06-04 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
US7666445B2
(en)
*
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
|
US20030232881A1
(en)
*
|
2000-10-27 |
2003-12-18 |
H. Lundbeck A/S |
Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
|
|
CA2364211A1
(en)
*
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
|
JP2004517112A
(ja)
*
|
2001-01-02 |
2004-06-10 |
ファルマシア・アンド・アップジョン・カンパニー |
新規薬物コンビネーション
|
|
ATE360425T1
(de)
*
|
2001-02-06 |
2007-05-15 |
Astrazeneca Ab |
Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
|
|
US20020123490A1
(en)
*
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
|
EA200301195A1
(ru)
*
|
2001-05-01 |
2004-04-29 |
Х. Лундбекк А/С |
Применение энантиомерно чистого эсциталопрама
|
|
US7034059B2
(en)
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
AU2003268026A1
(en)
*
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
AR042806A1
(es)
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
|
CN1989968B
(zh)
|
2002-12-27 |
2011-05-11 |
大塚制药株式会社 |
用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
|
|
EP1626722A1
(en)
*
|
2003-05-16 |
2006-02-22 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
|
MXPA05012391A
(es)
*
|
2003-05-16 |
2006-02-02 |
Pfizer Prod Inc |
Tratamiento de trastornos psicoticos y depresivos.
|
|
BRPI0410419A
(pt)
*
|
2003-05-16 |
2006-05-30 |
Pfizer Prod Inc |
tratamento para a ansiedade com ziprasidona
|
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
|
US20050032781A1
(en)
*
|
2003-08-06 |
2005-02-10 |
Elliot Ehrich |
Methods for administering active agents to CYP 2D6 sensitive patients
|
|
WO2005053703A1
(en)
|
2003-12-02 |
2005-06-16 |
Leslie James Sheldon |
Combination therapy for dementia, depression and apathy
|
|
CA2547639A1
(en)
|
2003-12-02 |
2005-06-16 |
B&B Beheer Nv |
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
|
|
US7855195B2
(en)
|
2003-12-02 |
2010-12-21 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1547650A1
(en)
*
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1699450A4
(en)
*
|
2003-12-23 |
2009-11-11 |
Darpharma Inc |
Simultaneous administration of dopamine receptor bindings
|
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
|
CA2553254C
(en)
*
|
2004-01-12 |
2013-12-17 |
The Trustees Of The University Of Pennsylvania |
Long-term delivery formulations and methods of use thereof
|
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
|
WO2006027800A1
(en)
*
|
2004-09-06 |
2006-03-16 |
Shasun Chemicals And Drugs Limited |
A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
|
|
EP1830844A1
(en)
*
|
2004-12-27 |
2007-09-12 |
Alpha 2 Pharmaceutical AB |
Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
|
|
CZ297214B6
(cs)
*
|
2005-02-02 |
2006-10-11 |
Zentiva, A. S. |
Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
|
|
UA97349C2
(uk)
*
|
2005-09-08 |
2012-02-10 |
Х. Луннбэк А/С |
Стійкі тверді склади сертиндолу
|
|
US20070093471A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals, Llc |
Compositions and methods for the administration clozapine formulations which modulate body weight
|
|
PL2120878T3
(pl)
*
|
2007-02-09 |
2015-01-30 |
Alphapharm Pty Ltd |
Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
|
RU2508096C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
|
|
RU2508106C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
|
|
CN101815519B
(zh)
*
|
2007-08-03 |
2013-08-21 |
吉瑞工厂 |
包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
|
|
EP2240173A4
(en)
*
|
2008-01-25 |
2013-07-17 |
Alphapharm Pty Ltd |
PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
|
|
WO2011018801A2
(en)
*
|
2009-08-12 |
2011-02-17 |
Genepharm India Pvt Ltd |
Solid oral dosage form of ziprasidone
|
|
WO2011057176A1
(en)
|
2009-11-06 |
2011-05-12 |
Forest Laboratories Holding Limited |
Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
AU2014361813A1
(en)
*
|
2013-12-13 |
2016-07-28 |
Ralph ANKENMAN |
Compositions and methods for treating dysregulated systems
|
|
NZ760790A
(en)
*
|
2014-02-07 |
2022-11-25 |
Neurocrine Biosciences Inc |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
MY193767A
(en)
|
2015-10-30 |
2022-10-27 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
CN108925135B
(zh)
|
2015-12-23 |
2025-09-19 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
|
US10336679B2
(en)
*
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
WO2018140092A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
|
ES3024958T3
(en)
|
2017-09-21 |
2025-06-05 |
Neurocrine Biosciences Inc |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
CN108938635A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种低剂量非典型抗精神病药物组合物
|
|
CN108926569A
(zh)
*
|
2018-08-24 |
2018-12-04 |
山西医科大学第医院 |
一种非典型抗精神病药物组合物
|
|
CN108938645A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种抗精神病药物组合物
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN111084778B
(zh)
*
|
2019-12-31 |
2022-06-24 |
北京鑫开元医药科技有限公司 |
一种奥氮平盐酸氟西汀胶囊及其制备方法
|